Compare Abbott Laboratories (ABT) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Williams-Sonoma, Inc. — how do they compare? Abbott Laboratories trades at $95.6 (market cap $166.94B), while Williams-Sonoma, Inc. trades at $216.77 (market cap $26.36B). The key difference: Abbott Laboratories is far larger — about 6.3× Williams-Sonoma, Inc.'s market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | WSM | |
|---|---|---|
Market Cap | $166.94B | $26.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $240.06 |
52-Week Low | $82.57 | $163.62 |
Enterprise Value | $193.69B | $27.20B |
Dividend Yield | 2.63% | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Williams-Sonoma (WSM) trades at $222.49, down 2.22% today, with a bullish technical signal and strong profitability metrics including 54.01% ROE and 13.81% net margin. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $2.03. Recent news highlights brand collaborations and dividend declarations, while cash flow trends show operational strength despite net outflows in 2025.
WSM presents a mixed outlook with robust fundamentals and analyst consensus leaning hold (60.72%), but risks include competitive pressures and macroeconomic sensitivity. The current price sits above the $215.50 consensus target, suggesting limited near-term upside despite strong operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
